Asset

Brimonidine tartrate

Ocugen Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03785340phase3completed2018-12-032019-02-25OcugenStudy of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
NCT03591874phase3terminated2018-12-232020-04-30OcugenStudy of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)